{
    "nct_id": "NCT04721015",
    "official_title": "A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors",
    "inclusion_criteria": "* Histologic solid tumor diagnosis (Part 1).\n* For Part 2 docetaxel combination therapy: EGFR WT expressing relapsed/refractory (R/R) non-small cell lung cancer (NSCLC) participants.\n* For Part 3 osimertinib combination therapy: mutEGFR-expressing RR NSCLC participants.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n* For Part 1 only - history of R/R disease that has progressed on all standard of care therapy.\n* For Part 2 only - history of RR NSCLC that has progressed after treatment with platinum-based chemotherapy regimen and either immune checkpoint inhibitor or targeted therapy and may not have been treated with prior single agent chemotherapy.\n* For Part 3 only - history of RR NSCLC that has progressed on osimertinib\n* Meet the laboratory values as described in the protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History (within 6 months) of congestive heart failure (defined as New York Heart Association, Class 2 or higher), ischemic cardiovascular event, cardiac arrhythmia requiring pharmacological or surgical intervention, pericardial effusion, or pericarditis.\n* Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.\n* For Part 3 only: History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, nor any evidence of active ILD or pneumonitis.",
    "miscellaneous_criteria": ""
}